Glenmark Pharmaceuticals Limited GLENMARK.BO Stock
Glenmark Pharmaceuticals Limited Price Chart
Glenmark Pharmaceuticals Limited GLENMARK.BO Financial and Trading Overview
| Glenmark Pharmaceuticals Limited stock price | 1050.85 INR |
| Previous Close | 642.1 INR |
| Open | 645.95 INR |
| Bid | 643 INR x 0 |
| Ask | 643.05 INR x 0 |
| Day's Range | 637.2 - 648.2 INR |
| 52 Week Range | 348.9 - 682 INR |
| Volume | 28.16K INR |
| Avg. Volume | 95.31K INR |
| Market Cap | 181.36B INR |
| Beta (5Y Monthly) | 0.699315 |
| PE Ratio (TTM) | 60.070095 |
| EPS (TTM) | -27.13 INR |
| Forward Dividend & Yield | 2.5 (0.38%) |
| Ex-Dividend Date | September 12, 2022 |
| 1y Target Est | 601.93 INR |
GLENMARK.BO Valuation Measures
| Enterprise Value | 215.14B INR |
| Trailing P/E | 60.070095 |
| Forward P/E | 16.725214 |
| PEG Ratio (5 yr expected) | 1.73 |
| Price/Sales (ttm) | 1.3961658 |
| Price/Book (mrq) | 1.9142169 |
| Enterprise Value/Revenue | 1.656 |
| Enterprise Value/EBITDA | 9.443 |
Trading Information
Glenmark Pharmaceuticals Limited Stock Price History
| Beta (5Y Monthly) | 0.699315 |
| 52-Week Change | 77.15% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 682 INR |
| 52 Week Low | 348.9 INR |
| 50-Day Moving Average | 564.61 INR |
| 200-Day Moving Average | 449.96 INR |
GLENMARK.BO Share Statistics
| Avg. Volume (3 month) | 95.31K INR |
| Avg. Daily Volume (10-Days) | 49.89K INR |
| Shares Outstanding | 282.17M |
| Float | 138.24M |
| Short Ratio | N/A |
| % Held by Insiders | 53.23% |
| % Held by Institutions | 20.46% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 2.5 |
| Trailing Annual Dividend Yield | 0.38% |
| 5 Year Average Dividend Yield | 50.00% |
| Payout Ratio | 0.2374 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 2.28% |
| Operating Margin (ttm) | 12.83% |
| Gross Margin | 65.07% |
| EBITDA Margin | 17.53% |
Management Effectiveness
| Return on Assets (ttm) | 5.71% |
| Return on Equity (ttm) | 3.91% |
Income Statement
| Revenue (ttm) | 129.9B INR |
| Revenue Per Share (ttm) | 460.18 INR |
| Quarterly Revenue Growth (yoy) | 14.00% |
| Gross Profit (ttm) | N/A |
| EBITDA | 22.78B INR |
| Net Income Avi to Common (ttm) | 2.97B INR |
| Diluted EPS (ttm) | 10.7 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 14.7B INR |
| Total Cash Per Share (mrq) | 52.09 INR |
| Total Debt (mrq) | 46.27B INR |
| Total Debt/Equity (mrq) | 47.03 INR |
| Current Ratio (mrq) | 1.957 |
| Book Value Per Share (mrq) | 335.777 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 6.25B INR |
| Levered Free Cash Flow (ttm) | 2.61B INR |
Profile of Glenmark Pharmaceuticals Limited
| Country | India |
| State | N/A |
| City | Mumbai |
| Address | Glenmark House |
| ZIP | 400099 |
| Phone | 91 22 4018 9999 |
| Website | https://www.glenmarkpharma.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes GBR 310, a biosimilar candidate, which is in Phase 2 clinical trial for the treatment of asthma and chronic idiopathic urticaria; and GRC 39815, a retinoid-related orphan receptor gamma t (ROR?t) inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; GRC 17536, a targeting transient receptor potential ankyrin 1 inhibitor, which is in Phase 2 clinical trial for the treatment of diabetic peripheral neuropathy; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. The company's pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, it offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Q&A For Glenmark Pharmaceuticals Limited Stock
What is a current GLENMARK.BO stock price?
Glenmark Pharmaceuticals Limited GLENMARK.BO stock price today per share is 1050.85 INR.
How to purchase Glenmark Pharmaceuticals Limited stock?
You can buy GLENMARK.BO shares on the BSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Glenmark Pharmaceuticals Limited?
The stock symbol or ticker of Glenmark Pharmaceuticals Limited is GLENMARK.BO.
Which industry does the Glenmark Pharmaceuticals Limited company belong to?
The Glenmark Pharmaceuticals Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Glenmark Pharmaceuticals Limited have in circulation?
The max supply of Glenmark Pharmaceuticals Limited shares is 282.19M.
What is Glenmark Pharmaceuticals Limited Price to Earnings Ratio (PE Ratio)?
Glenmark Pharmaceuticals Limited PE Ratio is now.
What was Glenmark Pharmaceuticals Limited earnings per share over the trailing 12 months (TTM)?
Glenmark Pharmaceuticals Limited EPS is -27.13 INR over the trailing 12 months.
Which sector does the Glenmark Pharmaceuticals Limited company belong to?
The Glenmark Pharmaceuticals Limited sector is Healthcare.